Sustained response following sorafenib therapy in an older adult patient with ... - UroToday PDF Print
UroTodayThe prognosis for patients with renal cell carcinoma is very poor, with a five-year survival rate of less than 10%. Sorafenib is an orally administered

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.

Notice: Undefined variable: query in /home/globaldi/public_html/components/com_joomlawatch/class.joomlawatch.db.php on line 129